Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
$538.60-0.74%
报价 2026-11-13
市值
$136.56B
EV
$113.41B
PE (TTM)
29.0x
预期 PE (FY2026)
29.6x
52 周区间距高点 -3.6%
$421.03$558.88
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| VRTXVertex Pharmaceuticals Incorporated | $136.56B | -0.7% | +10.6% | 86.3% | 29.0x | 23.5x | 42.6x | |
| MDTMedtronic plc | $131.58B | +1.9% | +8.0% | 62% | 24.2x | 14.8x | – | |
| BMYBristol-Myers Squibb Company PFD CONV 2 | $129.66B | +1.8% | +4.6% | 67.7% | 16.5x | 10.5x | 14.0x | |
| MCKMcKesson Corporation | $127.33B | +2.4% | +6.5% | 3.6% | 24.9x | 17.6x | 18.4x | |
| SYKStryker Corporation | $117.88B | -0.9% | +7.0% | 63.5% | 39.2x | 24.7x | 25.8x | |
| SNYSanofi | $116.66B | -0.2% | – | 71.7% | 8.9x | 9.7x | – | |
| CVSCVS Health Corporation | $114.32B | -0.5% | +5.2% | 13.8% | 51.2x | 17.8x | 7.3x | |
| HCAHCA Healthcare, Inc. | $104.25B | -0.3% | +4.5% | 14.9% | 16.7x | 9.9x | 17.7x | |
| GSKGSK plc | $101.41B | +0.5% | – | 72.5% | 13.7x | 7.8x | – | |
| 同行中位数 | – | – | +5.8% | 62.7% | 20.5x | 12.7x | 17.7x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。